London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
ChondroFiller is a Type I collagen scaffold injected into focal elbow cartilage defects that sets within 3–5 minutes and recruits progenitor cells to regenerate tissue — 70–85 per cent of patients in over 19,000 cases report meaningful symptom relief at three to five years, with zero serious complications recorded.
ChondroFiller sustains symptom relief in 70–85% of suitable patients over three to five years, filling defects with fibrocartilage—durable but structurally distinct from native cartilage.
A collagen scaffold injected under ultrasound recruits the body's own progenitor cells to rebuild shoulder cartilage. Evidence from other joints shows 70–85% of patients achieve symptom relief at three to five years, though shoulder-specific randomised controlled trial data do not yet exist.
The collagen scaffold in ChondroFiller injection works by recruiting repair cells from subchondral bone; lesions must therefore penetrate at least half the cartilage thickness, and candidacy depends on whether damage is focal (up to 6 cm²) or diffuse.
Advanced knee osteoarthritis typically damages two anatomically separate compartments — the articular cartilage surface and the synovial lining — simultaneously, yet most single-injection treatments address only one. A dual-injection protocol combines ChondroFiller, which scaffolds cartilage, with Arthrosamid, which cushions the synovial membrane.
ChondroFiller, a type I collagen hydrogel known as 'German knee gel', is injected into focal cartilage defects where it recruits the patient's own progenitor cells for tissue remodelling; it is neither a lubricant nor a treatment for generalised osteoarthritis.
